Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527874 | 0.86 | PDE4B (0.65) | KDM4EPDE4BALDH1A1L3MBTL1PDE4A | |
| SCHEMBL17677321 | 0.86 | PDE4B (0.41) | KDM4EPDE4BALDH1A1PDE4APDE4C | |
| SCHEMBL7862756 | 0.84 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7862625 | 0.83 | PDE4B (0.52) | KDM4EPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL11993042 | 0.83 | PDE4B (0.52) | KDM4EPDE4BALDH1A1PDE4APDE4C | |
| SCHEMBL18595818 | 0.81 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7862637 | 0.80 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15500061 | 0.79 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7866404 | 0.78 | PDE4B (0.48) | PDE4BALDH1A1PDE4APDE4CPDE4D | |
| SCHEMBL7864016 | 0.78 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2810946-B1 | 1,1'-[1,omega-alkyldiylbis(oxy)]bis[1,3-dihydro-2,1-benzoxaborole as volatile antimicrobial compounds | AGROFRESH INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | KDM4E 4296/4885PDE4B 776/4885ALDH1A1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.